Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2013 (International Society of Geriatric Oncology) /
Development of biosimilars for use in treating elderly patients

24th - 26th Oct 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.11.13
Views: 3978

Dr Etienne Brain - Institut Curie, Paris, France

Dr Etienne Brain talks to ecancer at the 2013 SIOG annual meeting about biosimiliars and the differences between these drugs and their generic versions.

As they are manufactured differently, biosimilars must go through a series of tests that guarantee their activity and efficacy. As a result, the drug that is manufactured is much cheaper to produce, but just as effective.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation